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Abstract
Background: The current treatments for anxiety disorders and depression have multiple adverse effects in addition
to a delayed onset of action, which has prompted efforts to find new substances with potential activity in these
disorders. Citrus aurantium was chosen based on ethnopharmacological data because traditional medicine refers to
the Citrus genus as useful in diminishing the symptoms of anxiety or insomnia, and C. aurantium has more recently
been proposed as an adjuvant for antidepressants. In the present work, we investigated the biological activity
underlying the anxiolytic and antidepressant effects of C. aurantium essential oil (EO), the putative mechanism of
the anxiolytic-like effect, and the neurochemical changes in specific brain structures of mice after acute treatment.
We also monitored the mice for possible signs of toxicity after a 14-day treatment.
Methods: The anxiolytic-like activity of the EO was investigated in a light/dark box, and the antidepressant activity
was investigated in a forced swim test. Flumazenil, a competitive antagonist of benzodiazepine binding, and the
selective 5-HT1A receptor antagonist WAY100635 were used in the experimental procedures to determine the
mechanism of action of the EO. To exclude false positive results due to motor impairment, the mice were
submitted to the rotarod test.
Results: The data suggest that the anxiolytic-like activity observed in the light/dark box procedure after acute (5
mg/kg) or 14-day repeated (1 mg/kg/day) dosing was mediated by the serotonergic system (5-HT1A receptors).
Acute treatment with the EO showed no activity in the forced swim test, which is sensitive to antidepressants. A
neurochemical evaluation showed no alterations in neurotransmitter levels in the cortex, the striatum, the pons,
and the hypothalamus. Furthermore, no locomotor impairment or signs of toxicity or biochemical changes, except
a reduction in cholesterol levels, were observed after treatment with the EO.
Conclusion: This work contributes to a better understanding of the biological activity of C. aurantium EO by
characterizing the mechanism of action underlying its anxiolytic-like activity.
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Background
Since the 1960s, the benzodiazepines, which improve
GABAergic neurotransmission, have been used extensively
to treat anxiety disorders. These compounds have shown
a clear efficacy, leading to their becoming the most widely
prescribed drugs worldwide [1]. However, many patients
fail to adequately respond to treatment [2], and the side
effects of benzodiazepines include sedation, muscle relaxation,
potentiation of the depressant effects of ethanol, antero-
grade amnesia, and addiction [3]. Buspirone, a non-
benzodiazepine azapirone agent that was introduced
in the late 1980s as a novel therapeutic agent for the
treatment of anxiety, functions by interacting with the
5-hydroxytryptamine1A (5-HT1A) receptor subtype [4].
However, the delayed onset of efficacy of buspirone (1–4
weeks), in contrast to the rapid effects observed with
benzodiazepines [5], has encouraged researchers to search
for a robust anxiolytic compound that has fewer side
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effects than benzodiazepines and a more immediate onset
of action than azapirones.
On the other hand, the various therapeutic pharmaceut-
ical classes (monoamine oxidase inhibitors, tricyclics and
selective serotonin reuptake inhibitors) used to treat de-
pression depend on monoamine (noradrenaline, dopamine
and mainly serotonin) availability in the brain. Despite the
large variety of medicines available, roughly half of the
patients seeking treatment do not respond to classical
antidepressants, and at least 2 weeks are necessary
for symptoms to be substantially ameliorated [6,7].
Antidepressants cause a robust set of side effects, such as
weight gain, constipation, memory disorders, and sleep
and sexual disorders, which vary in frequency and inten-
sity among the different classes of antidepressants [8].
Thus, the presence of multiple adverse side effects that
affect a considerable proportion of patients, as well as
the delayed onset of effects, drive the efforts to identify
new substances that can potentially treat anxiety and de-
pression [9,10].
Traditionally, populations in several countries have re-
lied on preparations obtained from Citrus species to
treat problems related to the nervous system, especially
symptoms of anxiety or insomnia [11-15]. Sedative and
anxiolytic-like effects have been described for the essen-
tial oil (EO) obtained from the peel of Citrus aurantium
L. [16,17]. In humans, drops of C. sinensis EO scattered
in the lobby of a dental office reduced the anxiety levels
of patients, specifically women [18]. Administered orally,
the EO derived from the petals and stamens of C.
aurantium reduced the preoperative anxiety of patients
scheduled for elective minor surgery [19].
More recently, preparations from Citrus species have
also been investigated for antidepressant activity in both
rodents and humans. EO preparations made from the
leaves of C. maxima [20] and C. limon [21] decreased
the immobility time of mice in the forced swim and tail
suspension tests, strengthening the suggestion that citrus
fragrance can reduce the dose of antidepressants
required to treat depressive subjects [22].
Our group found similar effects in experiments inves-
tigating the oral treatment of mice with the EOs
obtained from the peels of C. aurantium [23,24], C.
latifolia or C. reticulate [25]. The EOs increased the
amount of time spent in the open arms of the elevated
plus maze [23] and the lighted compartment in the
light/dark box test, in addition to reducing the number
of hidden marbles in the marble burying test [24,25].
While the elevated plus maze and the light/dark box are
sensitive to drugs such as benzodiazepines and are
models for generalized anxiety disorder [26], the marble
burying test is a model for obsessive-compulsive dis-
order [27], which benefits from treatment with
antidepressants. Thus, the activity profile observed for
EOs from Citrus species denotes a wide spectrum of action
given that the EOs were active in experimental models sen-
sitive to both anxiolytic and antidepressant drugs.
Considering this background, the aim of the present
work was to investigate the putative mechanism of the
anxiolytic-like effect and identify any neurochemical
changes in specific cerebral areas that result from acute
treatment with C. aurantium EO. To better characterize
their activity, the EO was also evaluated in anxiety tests
after a repeated 14-day oral treatment, where changes in
body weight, the integrity of the locomotor system and
serum biochemical parameters were monitored. Finally,
the EO was evaluated in experimental procedures related
to depressive disorders after oral or inhaled treatment.
Methods
Plant materials
C. aurantium (Rutaceae) ripe fruits were harvested be-
tween April and June of 2009 from adult plants in an or-
chard at the Department of Botany, Institute of
Biosciences, UNESP, Botucatu. The plant was identified
in the BOTU Herbarium of the Department of Botany,
UNESP, where a voucher specimen (#23123) had been
deposited.
EO extraction and phytochemical analysis
Immediately after harvesting the fruits were peeled and
the fresh peels were processed with a Clevenger appar-
atus, and the EO was obtained through hydrodistillation
while protected from light and heat. The EO was then
stored until use in the behavioral assays. Afterwards, an
aliquot was separated, and the EO was analyzed by gas
chromatography coupled with mass spectrometry as pre-
viously described [24].
Animals
All of the experiments were conducted in accordance
with the Ethical Principles in Animal Research adopted
by the Brazilian College of Animal Experimentation
(COBEA) and were approved by the Biosciences Insti-
tute – Ethics Committee for Animal Research (CEEA).
Adult Swiss male mice (30 days old) from a colony at
the UNESP Central Animal House facility were used in
all of the experiments after a one-week acclimation
period in the Animal House of the Department of
Pharmacology. Thus, the animals used were approxi-
mately 40 to 45 days old. The animals were maintained
under controlled temperature (21 ± 2°C) and light (12/12
light/dark cycle) conditions, with food and water ad
libitum until 2 h prior to the experimental procedures.
Drugs
Diazepam (DZP, Germed - EMS, Brazil) was used as the
standard anxiolytic drug, and imipramine hydrochloride
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(IM, Sigma-Aldrich, USA) was used as the standard anti-
depressant drug. Flumazenil (FLU, FlumazilW - Cristália,
Brazil) was utilized as a competitive antagonist of benzo-
diazepine binding, buspirone (BUSP, Sigma-Aldrich,
USA) was used as a partial agonist of 5-HT1A receptors,
and WAY100635 (WAY, Sigma-Aldrich, USA) was used
as a highly selective 5-HT1A antagonist. For the
intraperitoneal injections (i.p.), DZP, IM, and BUSP were
dissolved in isotonic saline solution (SAL, 0.9%). For oral
administration (p.o.), the EO or limonene (d-limonene,
98%, LIM, Sigma-Aldrich, USA), a major component of
the EO, were dissolved in 0.01% (v/v) polyoxyethylene
sorbitan monooleate (TW - Tween 80W, Sigma-Aldrich)
in saline, which was used to treat the control groups. All
of the solutions were freshly prepared on the test day
and were administered at 10 ml/kg of body weight, ex-
cept FLU, which was administered at 20 ml/kg due to
the concentration (0.1 mg/ml) of its commercial form.
Behavioral procedures
The behavior of the mice in the light/dark box and
forced swim tests was videotaped under white light illu-
mination using a video camera and a computer. The
digital video was subsequently reviewed, and behaviors
were scored by a highly trained observer who had been
blinded to the treatment conditions. In the rotarod test,
the behaviors were registered in real time. All of the ex-
perimental procedures took place between 9:00 am and
5:00 pm.
Light/Dark Box Test (LDB)
The apparatus used in our lab has previously been
described in detail [28], and our procedure was based on
the original protocol proposed by Crawley and Goodwin
[29]. Each animal was individually placed in the center of
the light compartment facing the dark compartment and
observed for 5 minutes after the first entry into the dark
compartment. During this period, we recorded the num-
ber of shuttle crossings (an activity-exploration index), the
number of rearings, and the time spent in the light com-
partment, which is the most consistent and useful meas-
ure for assessing anxiolytic-like activity [30,31].
Mice acutely pretreated (30 min) with EO at 1, 5, 10
or 50 mg/kg and mice repeatedly treated with EO at 1, 5
or 10 mg/kg/day for 14 days were used in this assay,
with the experimental session being carried out 30 min
after the last treatment. Despite the consistent activity of
1 mg/kg DZP (positive control) after a single treatment,
DZP was not effective in modifying the parameters
evaluated in the LDB after repeated treatments [28]. For
this reason, the positive control group in the repeated
treatment procedure received BUSP (10 mg/kg), a partial
agonist of 5-HT1A receptors that is recognized as a suit-
able anxiolytic with a slow onset of action [32].
The LDB test was also used to address a possible contri-
bution from the GABA-benzodiazepine or serotonergic
neurotransmission systems in the biological activity of EO.
Therefore, to assess the putative contribution of these
systems, mice were co-administered EO (5 mg/kg, p.o.)
and FLU (2 mg/kg, i.p.) or WAY (0.5 mg/kg, i.p.). FLU, a
competitive benzodiazepine antagonist, was administered
15 min after EO (group EO + FLU), while WAY, a specific
5-HT1A receptor antagonist, was administered 15 min be-
fore EO (group WAY + EO). The LDB procedure was
performed 30 min after the last drug treatment.
Rotarod Test (RRT)
At the end of the LDB procedure, the mice acutely or re-
peatedly treated with EO or used to study the EO mech-
anism of action were immediately placed onto the
Rotarod apparatus to verify the integrity of their motor
systems. Each animal was placed on a non-slippery plas-
tic rod 3.0 cm in diameter that was rotating at 5 rpm.
The mice were classified as “able” or “unable” based on
their ability to walk on the rotating bar for 1 min, with a
tolerance of up to three falls [33]. To avoid a bias due to
an incapacity not related to drug treatment, the mice
were assessed in the rotarod test 24 hours before the
start of the experimental procedure. Only those animals
that performed satisfactorily in this initial assessment
were evaluated in the RRT after the LDB.
Forced Swim Test (FST)
FST is consistently recognized as a model for assessing
antidepressant activity [34-36] and our experimental
conditions were previously detailed [28]. Briefly, each ani-
mal underwent a 15 min pre-test swim in a 13-cm column
of water (23 ± 2°C) in a transparent plastic cylinder (20.5
cm diameter). The pre-test session was conducted 24 h
prior to the 5-min swim tests, in which the immobility time
(in seconds) was determined by a post hoc evaluation of
the digital video using the Etholog 2.2 software [37]. Mice
treated with oral or inhaled EO were used in the FST.
For oral treatment, the mice received EO at 1, 5, 10 or
50 mg/kg according to the following schedule: the first
treatment (T1) was administered 1 h after finishing the
pre-test session, with the second and third treatments
administered 5 h (T2) and 30 min (T3) before the test
session, respectively. The inhaled treatments were given
in an acrylic box with cotton swabs soaked in 2 ml of
EO at 0.5%, 1.0%, or 2.5%, as described by Almeida et al.
[38]. Mice were individually placed into the box for 7
min to receive T1, T2, and T3 following the same time
schedule described for oral administration. The positive
control group was exposed to the inhalation box with
cotton swabs soaked in saline and treated with IM 30
mg/kg (i.p.), while the negative control group was
exposed to and treated with saline (i.p.).
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Toxicity and biochemical analyses
The mice treated with 1, 5 or 10 mg/kg EO for 14 days
were observed daily for signs and symptoms of toxicity
and were periodically weighed to evaluate changes in
body weight. Thirty minutes after the last treatment, the
mice were submitted to the LDB and the RRT, both of
which are described above.
After completion of the behavioral evaluation, blood
was collected for biochemical evaluation. The blood
samples were collected in tubes without anticoagulant,
which had been kept at room temperature for 30 min,
and were centrifuged at 4,000 rpm for 20 min at 4°C.
The serum samples were aspirated off and stored at −80°C
until analysis in a Cobas Mira PlusW Chemistry Analyzer
(Roche Diagnostic Systems, USA). The biochemistry
parameters measured were aspartate aminotransferase, al-
kaline phosphatase, urea, albumin, creatinine, total pro-
tein, cholesterol, and triglycerides.
Neurochemical evaluation
After 30 min of acute treatment with TW or EO (5 mg/
kg), the mice were euthanized and the brains rapidly
dissected (not more than 3 min after extraction) on ice.
The striatum, hypothalamus, pons, and frontal cortices
were isolated, weighed, and stored in liquid nitrogen.
For the neurochemical analyses, the tissues were
homogenized in 0.1 M perchloric acid by manual sonic-
ation, centrifuged at 10,000 rpm for 20 minutes to re-
move the supernatant, and stored at - 80°C until the
determination of monoamine levels.
The levels of neurotransmitters and their metabolites
(dopamine (DA), 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), and serotonin
(5HT) and 5-hydroxyindoleacetic acid (5HIAA)) were
measured by reversed-phase high performance liquid
chromatography (HPLC) using a system (model 6A,
Shimadzu, Kyoto, Japan) with an electrochemical de-
tector as described elsewhere [39]. Briefly, 20-μl samples
were loaded into a sample injector, and the mobile phase
was delivered at a constant rate of 1.2 ml/min. The
runtime for each sample was 15 min, and the
concentrations of all neurotransmitters and their
metabolites were expressed as nanograms per gram of
tissue (ng/g).
Statistical analysis
The quantitative data from the behavioral procedures
were subjected to Kruskal-Wallis non-parametric vari-
ance analysis followed by the Mann-Whitney test when
appropriate. The proportions in the RRT were compared
by Fisher’s exact test. The biochemical data were
analyzed by a one-way ANOVA followed by Dunnett’s
Multiple Comparison test, while the neurochemical data
were analyzed with an unpaired t-test. All of the
statistical analyses was made using GraphPad InStatW
version 3.02. The treated and TW groups were
compared, and differences were considered significant
when p ≤ 0.05.
Results
EO composition
Table 1 shows the results from the gas chromatography
coupled with mass spectrometry analysis of the C.
aurantium EO (yield: 0.50% v/w). The main EO com-
pound was identified by retention time and the Kovats
retention index [40] as monoterpene limonene (98.66%).
The other compounds detected in the EO included
β-pinene (0.41%) and β-myrcene (0.53%).
LDB procedure
The LDB was used to access the anxiolytic-like effect of
the EO after acute and repeated treatment, as well as to
investigate the effect of interference on the GABAergic
and serotonergic neurotransmission systems on the anti-
anxiety activity of the EO.
The results of the LDB (Figure 1, left panel) revealed a
significant increase in the amount of time spent in the
light chamber after the administration of a single dose of
5 mg/kg EO when compared to the TW group. An in-
crease in exploratory parameters (the number of
rearings) was observed after treatment with either DZP
or EO (5 or 50 mg/kg). The major compound in the EO
(limonene, 5 mg/kg, p.o.) was also evaluated after acute
treatment and did not modify behavioral parameters in
the LDB (Figure 1, central panel). Repeated treatment
with 1 mg/kg EO for 14 days modified the amount of
time spent in the illuminated side and the number of
transitions and rearings (Figure 1, right panel).
The results of the GABAergic and serotonergic interfer-
ence study are presented in Figure 2. As expected, FLU, a
competitive antagonist of the benzodiazepine receptor,
partially reversed the DZP effect, as the co-administration
of these compounds (DZP + FLU) significantly decreased
the magnitude of the DZP effect. Conversely, the EO effect
was not affected by the co-administration of FLU (OE +
FLU), suggesting that the EO does not function through
the GABA-benzodiazepine receptor complex.
Table 1 Chemical composition of the C. aurantium L. EO
obtained by gas chromatography coupled with mass
spectrometry
Constituent RT RI %
β-pinene 6.869 977 0.41
β -myrcene 7.261 991 0.53
Limonene 8.539 1037 98.66
ni 11.072 1100 0.41
RT, retention time; RI, retention index (experimental); ni, not identified.
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A similar approach was used to evaluate interference
with the 5HT1A serotonin receptor. Administering WAY
with the EO (WAY + EO) reversed all of the effects of
the EO in the LDB. Thus, it appears that the
serotonergic system, through 5HT1A receptor, is linked
to the anxiolytic-like action of the EO. To rule out the
possibility of a nonspecific effect, WAY was also co-
administered with DZP (WAY + DZP) without any ob-
servable effect.
RRT procedure
The results presented in Table 2 include the number of
“unable” mice in relation to the total number of mice
evaluated in each experimental group. Acute or repeated
treatment with the EO had no effect on the ability of the
mice to remain on the rotating bar. In the same way, the
individual or combined administration of the benzodi-
azepine or 5HT1A receptor agonists and antagonists and
the EO did not interfere with motor coordination as
evaluated by the RRT.
FST procedure
The results of the forced swim test after the oral or
inhaled administration of the EO are presented in
Table 3. The different doses or routes of EO admi-
nistration showed no signs of interference with
Figure 1 The effect of acute or repeated treatments on (A) the time (s) spent in the illuminated chamber, (B) the number of transitions
between chambers and (C) the number of rearings evaluated in the light/dark box test. The data are presented as the median and
interquartile range (Q1-Q3). TW: vehicle, 10 ml/kg (p.o.); DZP: diazepam, 1 mg/kg (i.p.); EO: Citrus aurantium essential oil, 1, 5, 10 or 50 mg/kg
(p.o.); LIM: d-limonene, 5 mg/kg (p.o.); BUSP: buspirone, 10 mg/kg (i.p.). The numbers in brackets indicate the number of mice in each group.
*p≤ 0.05, **p≤ 0.01 in relation to the TW group (Kruskal-Wallis followed by Mann-Whitney U-Test).
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immobility time, which is the main parameter indicat-
ing antidepressant activity in this experimental
procedure.
Toxicity and biochemical analyses
The 14-day EO treatment did not induce any observable
signs of toxicity; changes in body weight; or abnormal-
ities in the serum levels of aspartate aminotransferase,
alkaline phosphatase, urea, albumin, creatinine, total
protein, or triglycerides. The only parameter that was
altered was the serum total cholesterol, which was sig-
nificantly reduced by the 10 mg/kg EO treatment
(Table 4).
Neurochemical evaluation
Acute treatment with C. aurantium EO did not
change the levels of neurotransmitters or their
metabolites (DA, DOPAC, HVA, 5HT, and 5HIAA) in
the cortex, the striatum, the pons or the hypothal-
amus (Table 5).
Figure 2 The effect of blocking the benzodiazepine-GABA (left) or 5-HT1A (right) receptors on (A) the time (s) spent in the illuminated
chamber, (B) the number of transitions between chambers and (C) the number of rearings evaluated in the light/dark box test. The
data are presented as the median and interquartile range (Q1-Q3). TW: vehicle, 10 ml/kg (p.o.); DZP: diazepam, 1 mg/kg (i.p.); EO: C. aurantium
essential oil, 5 mg/kg (p.o.); FLU: flumazenil, 2.0 mg/kg (i.p.); WAY: WAY100635, 0.5 mg/kg (i.p.). The numbers in brackets indicate the number of
mice in each group. *p ≤ 0.05, **p ≤ 0.01 in relation to the TW group; # p≤ 0.05 between compared groups (Kruskal-Wallis followed by
Mann-Whitney U-Test).
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Discussion
Traditional populations usually consider the leaves and
flowers of Citrus species as a useful decoction [12,14] or
infusion [13,15] to treat nervous system disturbances.
Previously our group demonstrated the sedative and
anxiolytic-like effects of C. aurantium, C. latifolia, and
C. reticulata EO in mice [23-25].
Therefore, considering that the rate of comorbidity be-
tween anxiety and depression is approximately 60 to
70% in the general population [41] and that studies indi-
cate that these conditions have common genetic origins
[42], it is reasonable to propose that the same substance
can act as a therapeutic for both disorders. The present
work not only investigated the mechanism of action
underlying the anxiolytic-like effect of C. aurantium EO
but also investigated the antidepressant-like activity of
this EO.
The major compound present in the EO was limon-
ene, followed by β-myrcene. Both of these compounds
are biologically active in the central nervous system, as
mice treated with these compounds have shown
decreases in spontaneous activity, rearing, and grooming
in an open field test, and the compounds increased bar-
biturate sleeping time [43]. In the present work, limon-
ene did not modify the parameters evaluated in the LDB
at a dose of 5 mg/kg, which corresponds to the level
present in the effective dose of the EO (5 mg/kg). These
results corroborate previous reports [43] in which lim-
onene was not able to modify the parameters of
anxiolytic-like activity evaluated in the elevated plus
maze procedure. These findings strengthen the idea that,
in herbal preparations, the interactions between
compounds often result in biological activity that is
greater than the activity of isolated compounds, as noted
earlier [44].
The 5HT system has been implicated in the modula-
tion of anxiety levels, and some components of this sys-
tem promote anxiety while others reduce its symptoms
[45]. Since the introduction of buspirone as a novel
therapeutic agent for the treatment of anxiety, consider-
able interest in its therapeutic role in anxiety and mood
disorders has been generated [2]. Buspirone is a partial
agonist of 5-HT1A autoreceptors that acts as an antagon-
ist at certain postsynaptic 5-HT1A receptor sites. While
reports on the effect of the acute administration of
buspirone are inconclusive, chronic treatment causes an
anxiolytic-like effect [4,5].
According to our results, the EO showed anxiolytic
effects after acute (5 mg/kg) or 14-day repeated (1 mg/
kg/day) treatments, increasing all parameters evaluated
in the LDB. As previously reported for EO [23], the pro-
file of dose-response curve is not monotonic as usually
seen in classical pharmacology. In a monotonic curve,
the sign (negative or positive) of the slope is maintained
throughout the entire dose range. Conversely, in
nonmonotonic dose-response curve the slope changes
sign at some point along the range of doses, resulting in
a U- or inverted U-shape. In more complexes cases, a
nonmonotonic curve assumes a multiphasic shape, in
which the slope changes the sign in multiple points
along the curve. This complex situation emerges from
our results given that the dose of 5 mg/kg shows a sig-
nificant effect similar in magnitude to the dose of 50
mg/kg, with no effect at the lower (1mg/kg) and inter-
mediate (10 mg/kg) doses.
This phenomenon has puzzled researchers for more
than 50 years and recently a comprehensive overview
discusses and contributes to its better understanding
[46]. In spite of the main focus under endocrinology
field, examples have also emerging in different areas of
research such as toxicology, epidemiology and pharma-
cology [46,47]. Among the several putative mechanisms
which produce nonmonotonic responses (in cells,
tissues, and animals) stand out the cytotoxicity, cell-
specific and tissue-specific receptors and cofactors, re-
ceptor competition, superimposition of monotonic dose
Table 2 Effects of distinct treatments on motor
coordination as evaluated by the rotarod test
Acute treatment Repeated treatment
Group Fraction Group Fraction Group Fraction
TW 0.01% 1/7 FLU 2 0/5 TW 0.01% 0/5
DZP 1 0/8 WAY 0.5 1/5 BUSP 10 0/6
EO 1 0/5 DZP 1 + FLU 2 0/4 EO 1 0/5
EO 5 0/8 WAY 0.5 + DZP 1 1/5 EO 5 0/5
EO 10 1/6 EO 5 + FLU 2 0/4 EO 10 0/7
EO 50 0/6 WAY 0.5 + EO 5 0/5
The data are presented as the fraction of the total number of animals in each
experimental group that were unable to perform the test after acute or
repeated (14 days) treatments. TW: vehicle; DZP: diazepam; OE: C. aurantium
essential oil; BUSP: buspirone; FLU: flumazenil; WAY: WAY100635. The doses
are presented in mg/kg. The differences were compared in relation to the TW
group using Fisher’s exact test.
Table 3 Effects of oral or inhaled C. aurantium EO on
immobility time (s) in the forced swim test
Oral route Inhalatory route
Treatment n Immobility (s) Treatment n Immobility (s)
TW 5 226 (225–231) SAL 5 207 (203–219)
IM 6 156 (120–165) * IM 6 167 (164–171) *
EO 1 mg/kg 6 222 (215–238) EO 0.5% 8 215 (207–221)
EO 5 mg/kg 7 234 (217–241) EO 1.0% 8 194 (179–208)
EO 10 mg/kg 8 238(224–255) EO 2.5% 8 220 (175–234)
EO 50 mg/kg 6 217 (206–222)
The data are expressed as the median and interquartile range (Q1-Q3). TW:
vehicle; SAL: isotonic saline solution; IM: imipramine hydrochloride, 30 mg/kg
(i.p.); EO: C. aurantium essential oil. * p ≤ 0.05 in relation to the corresponding
TW or SAL group (Kruskal-Wallis followed by Mann-Whitney U-Test).
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responses and other events related with responses of a
biological system caused by products that have a com-
plex mixture of substances [46,48], including essential
oils.
The anxiolytic-like effects of the acute treatments were
not antagonized by FLU, a benzodiazepine antagonist,
but these effects were antagonized by the 5-HT1A spe-
cific antagonist WAY. Considering that benzodiazepines
are not effective in the LDB after chronic treatment [28]
and the reduction in the anxiolytic-like effect of the EO
after WAY administration, we can infer that the EO
functions through interactions with the serotonergic sys-
tem. However, we cannot discard the possibility that the
EO or its metabolites interact with other neurotransmis-
sion systems. Increased 5HT and DA synthesis were
observed in the prefrontal cortex and hippocampus of
mice after the inhalation of lemon oil vapor (a species
from the Citrus genus), suggesting that lemon oil vapor
possibly affects the response to DAnergic activity by
modulating the 5HTnergic system [49]. In our assess-
ment of DA, 5HT, and their metabolites, no alterations
in the levels of these neurotransmitters were observed in
the cerebral areas evaluated after acute treatment with
the EO. Higher EO doses and/or repeated treatment
could reveal this effect on neurotransmitter systems.
Contradicting our expectations and previous reports
[20,21], the EO was unable to modify immobility time in
the FST, an experimental model of depression. The use
of 5-HT1A ligands for the treatment of depressive
disorders shows inconsistent results [50]. This inconsist-
ency may be related to differences in the intrinsic
activity and potency of 5-HT1A drugs that appear to de-
pend on the brain region [4].
Despite the effect observed in a study treating rats
with the same concentration used in our procedure [16],
we could not find an anxiolytic-like effect after inhaled
exposure to EO. Similarly, no antidepressant-like effect
was found in the FST after the inhalation of EO.
Finally, in agreement with a subchronic 28-day toxicity
study of C. aurantium extracts in mice [51], the 14-day
repeated EO treatment in this study showed no deleteri-
ous consequences. Daily inspection and periodic weighing
showed no differences in general aspect, body weight, or
the biochemical parameters of the experimental groups,
except for a decrease in total cholesterol. This finding is
not unexpected because polymethoxylated flavones, which
are compounds found in a variety of citrus fruits, have
been shown to cause a hypolipidemic response in
hamsters with experimental hypercholesterolemia [52],
and the supplementation of 2% d-limonene, a major com-
pound in C. aurantium, to a high fat diet in Wistar rats
reversed the diet-induced changes in lipid levels and lipid
peroxidation [53].
Conclusion
C. aurantium EO possesses a significant anxiolytic-like
activity, and the present results strongly suggest the in-
volvement of 5-HT1A-receptors. We believe that these
results are promising, as EO treatment might be
considered a complementary therapy for the treatment of
anxiety disorders. However, further studies are necessary
to explore the detailed mechanism of EO action on
Table 4 Changes in body weight and biochemical parameters after 14 days of treatment with C. aurantium EO
Treatment n Body weight (g) Biochemical parameters
Day 1 Day 14 UR (mg/dL) CR (mg/dL) TPRO (g/dL) ALB (g/dL) AST (UI/L) AP (UI/L) CHOL (mg/dL) TRGL (mg/dL)
Tween 6 35 ± 4 43 ± 7 64.5 ± 10.1 0.3 ± 0.1 7.0 ± 0.1 3.9 ± 0.3 320.4 ± 85.5 164.8 ± 74.2 158.8 ± 35.2 173.8 ± 42.5
EO 1 mg/kg 7 34 ± 6 41 ± 10 64.4 ± 13.7 0.3 ± 0.2 7.9 ± 1.9 4.5 ± 0.9 334.2 ±5 2.7 131.4 ± 44.7 131.4 ± 27.2 143.6 ± 50.8
EO 5 mg/kg 6 34 ± 2 42 ± 4 65.3 ± 13.7 0.2 ± 0.1 6.9 ± 0.8 4.2 ± 0.9 377.4 ± 83.6 161.9 ± 64.0 135.2 ± 15.6 130.8 ± 37.5
EO 10 mg/kg 7 34 ± 4 40 ± 5 64.1 ± 11.9 0.2 ± 0.0 6.9 ± 0.6 3.9 ± 0.4 309.5 ± 45.2 123.3 ± 34.9 121.9 ± 20.4 * 132.7 ± 33.4
The data are presented as the mean ± SD. UR (urea), CR (creatinine), TPRO (total protein), ALB (albumin), AST (aspartate aminotransferase), AP (alkaline
phosphatase), CHOL (cholesterol), TRGL (triglycerides). * p ≤ 0.05 in relation to the control group (one-way ANOVA followed by the Dunnett’s Multiple
Comparisons Test).
Table 5 Neurotransmitter levels and their metabolites (ng/g) after acute oral treatment with C. aurantium EO (5 mg/kg)
Structures and treatments
Cortex Striatum Pons Hypothalamus
TW EO TW EO TW EO TW EO
DA 845.6 ± 239.9 (10) 895.6 ± 321.3 (7) 8324.3 ± 517.1 (11) 8331.2 ± 1040.1 (7) 15.2 ± 3.8 (10) 18.6 ± 6.2 (7) 53.1 ± 3.8 (10) 58.3 ± 5.8 (6)
DOPAC 94.6 ± 15.9 (12) 85.6 ± 17.4 (8) 437.4 ± 44.5 (11) 415.5 ± 49.9 (7) 11.6 ± 1.6 (11) 8.4 ± 1.1 (8) 58.6 ± 5.6 (12) 64.2 ± 4.7 (8)
HVA 427.3 ± 80.4 (12) 567.8 ± 112.5 (8) 1121.9 ± 96.8 (11) 1384.9 ± 193.5 (7) 317.2 ± 87.9 (11) 388.3 ± 141.3 (8) 236.2 ± 36.8 (12) 388.8 ± 74.5 (8)
5HT 1246.9 ± 85.8 (12) 1270.1 ± 81.0 (8) 1686.3 ± 102.4 (11) 1665.9 ± 170.9 (7) 2782.4 ± 259.8 (11) 2075.4 ± 309.9 (8) 1660.1 ± 126.2 (12) 1599.2 ± 113.9 (8)
5HIAA 192.7 ± 17.5 (12) 229.3 ± 33.7 (8) 317.1 ± 30.9 (11) 320.3 ± 40.0 (7) 879.2 ± 69.5 (10) 644.1 ± 76.4 (7) 341.7 ± 20.9 (12) 310.9 ± 19.4 (8)
TW (tween). The data are presented as the mean ± SEM. Any differences were compared with an unpaired t-test. The number of animals is different for each
group because some structures could not be evaluated due to technical reasons.
Costa et al. BMC Complementary and Alternative Medicine 2013, 13:42 Page 8 of 10
http://www.biomedcentral.com/1472-6882/13/42
binding sites. Moreover, the EO appears to be well
tolerated, as none of the different doses caused alterations
or showed signs of toxicity.
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